CCND1 and neoplasm: Moreover, mutations in CCND1, which prevent the degradation of cyclin D1 by AMBRA1, a substrate receptor (SR) of a CUL4-RING ubiquitin ligase (CRL4) complex that targets all three D-type cyclins for proteasome-mediated degradation, have been reported in a variety of tumor types (Simoneschi et al., 2021; Chaikovsky et al., 2021; Martínez-Jiménez et al., 2020).